Catheter Precision Enters Loan Agreement
Ticker: VTAK · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1716621
| Field | Detail |
|---|---|
| Company | Catheter Precision, Inc. (VTAK) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $500,000, $150,000, $250,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt, financing
TL;DR
Catheter Precision just signed a loan agreement, details TBD.
AI Summary
On July 25, 2024, Catheter Precision, Inc. entered into a material definitive agreement, specifically a loan agreement with an unnamed lender. This agreement creates a direct financial obligation for the registrant. The filing does not specify the dollar amount or terms of the loan.
Why It Matters
This filing indicates Catheter Precision, Inc. has secured new financing, which could impact its operational capacity and financial structure.
Risk Assessment
Risk Level: medium — The company has entered into a new financial obligation, the terms and impact of which are not fully disclosed in this initial filing.
Key Players & Entities
- Catheter Precision, Inc. (company) — Registrant
- July 25, 2024 (date) — Date of earliest event reported
FAQ
What is the principal amount of the loan agreement?
The filing does not specify the principal amount of the loan agreement.
Who is the lender in this material definitive agreement?
The filing does not disclose the identity of the lender.
What are the key terms and conditions of the loan agreement?
The filing does not provide details on the terms and conditions of the loan agreement.
What is the purpose of this new financial obligation for Catheter Precision, Inc.?
The filing does not state the specific purpose for which the loan was obtained.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on July 25, 2024.
Filing Stats: 834 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-07-30 17:07:51
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VTAK NYSE American Indic
- $500,000 — charitable trust (the "Trust"), loaned $500,000 to Catheter Precision, Inc. (the "Compa
- $150,000 — 0 June 25, 2024 FatBoy Capital, L.P. $150,000 July 1, 2024 FatBoy Capital, L.P. $2
- $250,000 — 00 July 1, 2024 FatBoy Capital, L.P. $250,000 July 18, 2024 FatBoy Capital, L.P. $
- $100,000 — 0 July 18, 2024 FatBoy Capital, L.P. $100,000 The Note and the debt evidenced thereb
Filing Documents
- rmed_8k.htm (8-K) — 31KB
- rmed_ex101.htm (EX-10.1) — 35KB
- 0001654954-24-009649.txt ( ) — 198KB
- rmed-20240725.xsd (EX-101.SCH) — 6KB
- rmed-20240725_lab.xml (EX-101.LAB) — 14KB
- rmed-20240725_cal.xml (EX-101.CAL) — 1KB
- rmed-20240725_pre.xml (EX-101.PRE) — 9KB
- rmed-20240725_def.xml (EX-101.DEF) — 2KB
- rmed_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. 8% Short Term Promissory Note due August 30, 2024 (the "Note") On July 25, 2024, the Jenkins Family Charitable Institute, a Louisiana charitable trust (the "Trust"), loaned $500,000 to Catheter Precision, Inc. (the "Company") in exchange for the Note. The Note has a maturity date of August 30, 2024, and bears interest at the rate of 8% per annum. David A. Jenkins, Executive Chair and Chief Executive Officer of the Company, was the Settlor and Initial Trustee of the Trust, and the current Trustee of the Trust is Mr. Jenkins' adult daughter. This Note is in addition to the following 8% Short Term Promissory Notes due August 30, 2024, issued in connection with prior loans extended to the Company by Mr. Jenkins and FatBoy Capital, L.P., an entity controlled by Mr. Jenkins, as previously reported: Date of Note Holder Principal Amount May 30, 2024 David A. Jenkins $500,000 June 25, 2024 FatBoy Capital, L.P. $150,000 July 1, 2024 FatBoy Capital, L.P. $250,000 July 18, 2024 FatBoy Capital, L.P. $100,000 The Note and the debt evidenced thereby, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owing when due, material breach of representations or warranties by us (unless waived by the holder of the Note or cured within 10 days following notice) and/or certain events involving a discontinuation of our business or certain types of proceedings involving insolvency, bankruptcy, receivership and the like. In addition to his roles as a director and officer of the Company, Mr. Jenkins and his affiliates beneficially own over 10% of the common stock of the Company, Series X Preferred convertible into over 800,000 shares of Company common stock (subject to certain conditions), stock options issued by the Company, and the rights to receive royalties on sales of our LockeT devic
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 8% Short Term Promissory Note Due August 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: July 30, 2024 By: /s/ Margrit Thomassen Margrit Thomassen Interim Chief Financial Officer 3